PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904)

MLA

C. Lemanski, et al. “PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in Combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904).” Radiotherapy and Oncology, vol. 161, Aug. 2021, pp. S82–83. EBSCOhost, https://doi.org/10.1016/s0167-8140(21)07247-9.

APA

C. Lemanski, Xavier Mirabel, Astrid Lièvre, Philippe Ronchin, Véronique Vendrely, Gilles Breysacher, C. Lepage, Thomas Aparicio, K. Le-Malicot, Nicolas Magné, Ariane Darut-Jouve, E. Thimonier, M. Minsat, C. De La Fouchardiere, C. Belletier, & D. Argo-Leignel. (2021). PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904). Radiotherapy and Oncology, 161, S82–S83. https://doi.org/10.1016/s0167-8140(21)07247-9

Chicago

C. Lemanski, Xavier Mirabel, Astrid Lièvre, Philippe Ronchin, Véronique Vendrely, Gilles Breysacher, C. Lepage, et al. 2021. “PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in Combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904).” Radiotherapy and Oncology 161 (August): S82–83. doi:10.1016/s0167-8140(21)07247-9.